Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
被引:204
作者:
Parks, Mary
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Metab & Endocrinol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USAUS FDA, Div Metab & Endocrinol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA
Parks, Mary
[1
]
Rosebraugh, Curtis
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Off Drug Evaluat 2, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USAUS FDA, Div Metab & Endocrinol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA
Rosebraugh, Curtis
[2
]
机构:
[1] US FDA, Div Metab & Endocrinol Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[2] US FDA, Off Drug Evaluat 2, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA